Lasa Supergenerics Profile
Key Indicators
- Authorised Capital ₹ 100.33 Cr
as on 10-07-2024
- Paid Up Capital ₹ 50.10 Cr
as on 10-07-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 84.64 Cr
as on 10-07-2024
- Revenue -4.24%
(FY 2023)
- Profit -619.57%
(FY 2023)
- Ebitda -142.18%
(FY 2023)
- Net Worth -20.42%
(FY 2023)
- Total Assets -17.75%
(FY 2023)
About Lasa Supergenerics
It is listed on the Bombay Stock Exchange(BSE) under the ticker symbol 540702 and on the National Stock Exchange(NSE) under LASA.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 100.33 Cr and a paid-up capital of Rs 50.10 Cr.
The company has closed loans amounting to ₹84.64 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Lasa Supergenerics Limited India are Mitti Jain as COMPANY SECRETARY and Ravishankar Kabra as Cfo. Manali Bhagtani, Ajay Sukhwani, Ekta Gurnasinghani, and Three other members serve as directors at the Company.
Industry
Company Details
- Location
Raigarh, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Lasa Supergenerics Limited offer?
Lasa Supergenerics Limited offers a wide range of products and services, including Insecticides and Pesticides, Acaricide, Veterinary Medicines, Veterinary Chemicals, Animal Medicines & Health Care, Anthelmintics, Antibacterial Drugs, Ofloxacin Ornidazole Tablets, Hand Sanitizers & Personal Hygiene, Antiseptic Liquid & Cream.
Who are the key members and board of directors at Lasa Supergenerics?
Executive Team (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mitti Jain | Company Secretary | 21-Mar-2023 | Current |
Omkar Pravin  | Managing Director | 11-Mar-2016 | Current |
| Ravishankar Kabra | CFO | 13-Aug-2018 | Current |
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Manali Bhagtani | Director | 12-Feb-2018 | Current |
| Hardesh Tolani | Director | 02-May-2017 | Current |
| Ajay Sukhwani | Director | 02-May-2017 | Current |
| Ekta Gurnasinghani | Director | 02-May-2017 | Current |
| Umesh Pawar | Additional Director | 11-Mar-2024 | Current |
Financial Performance of Lasa Supergenerics.
Lasa Supergenerics Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.24% decrease. The company also saw a substantial fall in profitability, with a 619.57% decrease in profit. The company's net worth observed a substantial decline by a decrease of 20.42%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Lasa Supergenerics?
In 2023, Lasa Supergenerics had a promoter holding of 53.65% and a public holding of 46.35%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Amarnath Securities LimitedActive 30 years 2 monthsAjay Sukhwani and Omkar Pravin are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 26 Apr 2018 | ₹6.03 Cr | Satisfied |
Others Creation Date: 31 Mar 2018 | ₹1.82 Cr | Satisfied |
Axis Bank Limited Creation Date: 28 Nov 2012 | ₹76.79 Cr | Satisfied |
How Many Employees Work at Lasa Supergenerics?
Lasa Supergenerics has a workforce of 326 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Lasa Supergenerics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Lasa Supergenerics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
